Clinical Trial Update: Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML) [Phase 1, Phase 2]

View source ↗

Summary

Early-phase trial of anti-Siglec-6 CAR-T therapy for relapsed/refractory acute myeloid leukemia is being investigated in Phase 1/2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Anti-siglec-6 CAR-T Cell Therapy (CAR-T directed at Siglec-6)

Snippet

Sponsor: Xuzhou Medical University | Conditions: Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse | Phase 1, Phase 2 | Status: UNKNOWN